110 results on '"MARGOLIN, DAVID A."'
Search Results
2. Elucidating the Molecular Biomarkers Associated with Increase Responsiveness to a Cyclic Peptide CXCR4 Antagonist, LY2510924, in an Orthotopic Xenograft Mice Model on Colorectal Cancer Tumor Growth and Metastasis
3. Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer
4. The Role of Bowel Preparation in Colorectal Surgery
5. An Optimal Orthotopic Mouse Model for Human Colorectal Cancer Primary Tumor Growth and Spontaneous Metastasis
6. Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) (P6.366)
7. Durable Clinical Outcomes With Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (P6.369)
8. Alemtuzumab Provides Durable Efficacy and Safety Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS II (TOPAZ Study) (P6.368)
9. Alemtuzumab-Treated Patients Experienced Decreased MRI Disease Activity and Slowing of Brain Volume Loss Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS I (TOPAZ Study) (S36.003)
10. Alemtuzumab Reduced MRI Lesions and the Rate of Brain Volume Loss in CARE-MS II Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) (P5.031)
11. Durable Reduction in MRI Disease Activity and Slowing of Brain Volume Loss in Alemtuzumab-Treated Patients With Active RRMS: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) (P6.375)
12. Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) (P6.376)
13. Active RRMS Patients Treated with Alemtuzumab Experience Durable Reductions in MRI Disease Activity and Slowing of Brain Volume Loss: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (P6.367)
14. Morbidity Following Coloanal Anastomosis: A Comparison of Colonic J-Pouch vs Straight Anastomosis
15. Alemtuzumab CARE-MS I 5-year follow-up
16. Alemtuzumab CARE-MS II 5-year follow-up
17. Alemtuzumab Durably Slows Brain Volume Loss Over 6 Years in the Absence of Continuous Treatment in Patients With Active RRMS Who Were Treatment-Naive (CARE-MS I) or Had an Inadequate Response to Prior Therapy (CARE-MS II) (P2.104)
18. Safety, Tolerability, and Pharmacodynamics of Intravenous and Subcutaneous Doses of the Anti-CD52 Antibody GLD52 in Patients With Progressive MS: A Randomized, Controlled, Single Ascending Dose Trial (P5.375)
19. Improvements in Quality of Life Over 6 Years in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Alemtuzumab: Results From the CARE-MS II Extension Study (P5.342)
20. Alemtuzumab Improves Clinical Outcomes Over 4 Years in Patients With Relapsing- Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up (P5.332)
21. Alemtuzumab Suppresses MRI Disease Activity Over 6 Years in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy: CARE-MS II (P5.339)
22. Efficacy and Safety of Alemtuzumab in Patients With RRMS Is Durable Over 10 Years: Follow-up From the CAMMS223 Study (P5.338)
23. Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II) (S24.006)
24. Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up (P5.360)
25. Durable Efficacy of Alemtuzumab in CARE-MS II Patients With RRMS With Disease Activity (Relapse) Between Courses 1 and 2 (P5.349)
26. Alemtuzumab Decreased MRI Disease Activity Over 4 Years in Patients Who Switched From SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up (S12.007)
27. Clinical and Radiologic Benefits of Alemtuzumab Over 5 Years in Patients of African Descent With Active RRMS (P5.336)
28. Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study (S12.006)
29. Alemtuzumab Reduces the Rate of Brain Volume Loss in RRMS Patients Over 4 Years Following Switch From SC IFNB-1a: CARE-MS Extension Study (S12.003)
30. Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I) (S24.005)
31. Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study (S10.002)
32. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
33. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
34. Comparison of 30-Day Postoperative Outcomes after Laparoscopic vs Robotic Colectomy
35. Durable Efficacy of Alemtuzumab Over 10 Years: Long-Term Follow-Up of Patients with RRMS from the CAMMS223 Study (P3.053)
36. Treatment-Naive Patients with Highly Active RRMS Demonstrated Durable Efficacy with Alemtuzumab over 5 Years (S51.003)
37. Treatment-Naive Patients with Active RRMS Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS I Study (S51.004)
38. Patients Who Discontinued SC IFNB-1a and Switched to Alemtuzumab in the CARE-MS II Extension Study Show Durable Reduction in New Lesion Activity (P3.025)
39. Patients Who Had Highly Active RRMS and an Inadequate Response to Prior Therapy Demonstrated Durable Efficacy with Alemtuzumab: 5-Year Follow-Up of the CARE-MS II Study (P6.164)
40. Durable Efficacy in RRMS Patients Receiving Two Annual Courses of Alemtuzumab and No Additional Treatment for 4 Years: Pooled Analysis of CARE-MS I and II (S51.005)
41. Patients with Active RRMS and an Inadequate Response to Prior Therapy Demonstrate Durable Improvements in Relapse and Disability Following Treatment with Alemtuzumab: 5-Year Follow-Up of the CARE-MS II Study (P3.022)
42. Treatment-Naive Patients with Active RRMS Who Received Alemtuzumab Demonstrate Durable Suppression of New MRI Lesion Formation: 5-Year Follow-Up of the CARE-MS I Study (S51.002)
43. RRMS Patients Switching from SC IFNB-1a to Alemtuzumab in the CARE-MS I and II Extension Study Have a Reduced Rate of Brain Volume Loss (P6.183)
44. Patients Who Switched from SC IFNB-1a to Alemtuzumab in the CARE-MS II Extension Study Show Durable Improvements in Clinical Outcomes (P3.024)
45. Incidence and Timing of Thyroid Adverse Events in Patients with RRMS Treated with Alemtuzumab through 5 Years of the CARE-MS Studies (P2.086)
46. Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study (S51.001)
47. Patients with Active RRMS and an Inadequate Response to Prior Therapy Who Received Alemtuzumab Demonstrate Durable Suppression of New MRI Lesion Formation: 5-Year Follow-Up of the CARE-MS II Study (P3.112)
48. Patients Who Discontinued SC IFNB-1a and Switched to Alemtuzumab in the CARE-MS I Extension Study Show Durable Reduction in New Lesion Activity (P3.026)
49. Patients with RRMS Who Had an Inadequate Response to a Prior Therapy Demonstrated Durable Improvement in EDSS Functional Systems Scores Over 5 Years with Alemtuzumab (P6.186)
50. Patients Who Switched from SC IFNB-1a to Alemtuzumab in the CARE-MS I Extension Study Show Durable Improvements in Clinical Outcomes (P3.104)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.